Esperion Therapeutics ESPR Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherAccruedLiabilities.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's change in accrued liabilities?
- Esperion Therapeutics (ESPR) reported change in accrued liabilities of -$4.86M in Q1 2026.
- How has Esperion Therapeutics's change in accrued liabilities changed year-over-year?
- Esperion Therapeutics's change in accrued liabilities decreased by 421.9% year-over-year, from -$932K to -$4.86M.
- What is the long-term trend for Esperion Therapeutics's change in accrued liabilities?
- Over 2 years (2023 to 2025), Esperion Therapeutics's change in accrued liabilities has grown at a 18.9% compound annual growth rate (CAGR), from $22.1M to $31.22M.
- What does change in accrued liabilities mean?
- Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.